Characteristic expression of fukutin in gastric cancer among atomic bomb survivors

Pham,Trang  T.B.; Oue,Naohide; Yamamoto,Manabu; Fujihara,Megumu; Ishida,Teruyoshi; Mukai,Shoichiro; Sakamoto,Naoya; Sentani,Kazuhiro; Yasui,Wataru

doi:10.3892/ol.2016.5520

Characteristic expression of fukutin in gastric cancer among atomic bomb survivors

Authors:
- Trang T.B. Pham
- Naohide Oue
- Manabu Yamamoto
- Megumu Fujihara
- Teruyoshi Ishida
- Shoichiro Mukai
- Naoya Sakamoto
- Kazuhiro Sentani
- Wataru Yasui
View Affiliations

Affiliations: Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan, Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Department of Pathology, Hiroshima Red Cross Hospital and Atomic‑Bomb Survivors Hospital, Hiroshima 730‑8619, Japan, Department of Surgery, Hiroshima Red Cross Hospital and Atomic‑Bomb Survivors Hospital, Hiroshima 730‑8619, Japan
Published online on: December 20, 2016 https://doi.org/10.3892/ol.2016.5520
Pages: 937-941

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately 70 years have passed since the atomic bombs were dropped on Nagasaki and Hiroshima. To elucidate potential biomarkers and possible mechanisms of radiation‑induced cancer, the expression of FKTN, which encodes fukutin protein and causes Fukuyama‑type congenital muscular dystrophy, was analyzed in gastric cancer (GC) tissue samples from atomic bomb survivors. Expression of cluster of differentiation (CD) 10 was also evaluated, as it has previously been observed that positive fukutin expression was frequently noted in CD10‑positive GC cases. In the first cohort from Hiroshima Red Cross Hospital and Atomic‑Bomb Survivors Hospital (Hiroshima, Japan; n=92), 102 (53%) of the GC cases were positive for fukutin. Expression of fukutin was not associated with exposure status, but was associated with CD10 expression (P=0.0001). The second cohort was from Hiroshima University Hospital (Hiroshima, Japan; n=86), and these patients were also in the Life Span Study cohort, in which atomic bomb radiation doses were precisely estimated using the DS02 system. Expression of fukutin was detected in 58 (67%) of GC cases. GC cases positive for fukutin were observed more frequently in the low dose‑exposed group than in the high dose‑exposed group (P=0.0001). Further studies with a larger cohort, including precise radiation dose estimation, may aid in clarifying whether fukutin could serve as a potential biomarker to define radiation‑induced GC in atomic‑bomb survivors.

View Figures

View References

1	Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M and Izumi S: Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. Radiat Res. 137:(2 Suppl). S17–S67. 1994. View Article : Google Scholar : PubMed/NCBI
2	Pierce DA, Shimizu Y, Preston DL, Vaeth M and Mabuchi K: Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950–1990. 1996. Radiat Res. 146:61–87. 2012. View Article : Google Scholar
3	Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H and Kodama K: Studies of the mortality of atomic bomb survivors, Report 14, 1950–2003: An overview of cancer and noncancer diseases. Radiat Res. 177:229–243. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sakata R, Grant EJ, Furukawa K, Misumi M, Cullings H, Ozasa K and Shore RE: Long-term effects of the rain exposure shortly after the atomic bombings in Hiroshima and Nagasaki. Radiat Res. 182:599–606. 2014. View Article : Google Scholar : PubMed/NCBI
5	Global Burden of Disease Cancer Collaboration, . Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G and Woodbrook R: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N: Molecular pathology of gastric cancer: Research and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
8	Preston DL, Shimizu Y, Pierce DA, Suyama A and Mabuchi K: Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950–1997. 2003. Radiat Res. 178:AV146–AV172. 2012. View Article : Google Scholar : PubMed/NCBI
9	Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K and Kodama K: Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res. 168:1–64. 2007. View Article : Google Scholar : PubMed/NCBI
10	Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE and Harris CC: p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 342:1520–1521. 1993. View Article : Google Scholar : PubMed/NCBI
11	Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K and Hamatani K: The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog. 46:242–248. 2007. View Article : Google Scholar : PubMed/NCBI
12	Iwamoto KS, Mizuno T, Tokuoka S, Mabuchi K and Seyama T: Frequency of p53 mutations in hepatocellular carcinomas from atomic bomb survivors. J Natl Cancer Inst. 90:1167–1168. 1998. View Article : Google Scholar : PubMed/NCBI
13	Oue N, Sentani K, Sakamoto N, Motoshita J, Nishisaka T, Fukuhara T, Matsuura H, Sasaki H, Nakachi K and Yasui W: Characteristic gene expression in stromal cells of gastric cancers among atomic-bomb survivors. Int J Cancer. 124:1112–1121. 2009. View Article : Google Scholar : PubMed/NCBI
14	Naito Y, Oue N, Pham TT, Yamamoto M, Fujihara M, Ishida T, Mukai S, Sentani K, Sakamoto N, Hida E, et al: Characteristic miR-24 expression in gastric cancers among atomic bomb survivors. Pathobiology. 82:68–75. 2015. View Article : Google Scholar : PubMed/NCBI
15	Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM and Yasui W: Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: Expression of DSC2 in gastric cancer with intestinal phenotype. J Pathol. 221:275–284. 2010. View Article : Google Scholar : PubMed/NCBI
16	Oo HZ, Sentani K, Sakamoto N, Anami K, Naito Y, Oshima T, Yanagihara K, Oue N and Yasui W: Identification of novel transmembrane proteins in scirrhous-type gastric cancer by the Escherichia coli ampicillin secretion trap (CAST) method: TM9SF3 participates in tumor invasion and serves as a prognostic factor. Pathobiology. 81:138–148. 2014. View Article : Google Scholar : PubMed/NCBI
17	Oue N, Sentani K, Sakamoto N and Yasui W: Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 106:951–958. 2015. View Article : Google Scholar : PubMed/NCBI
18	Oo HZ, Sentani K, Mukai S, Hattori T, Shinmei S, Goto K, Sakamoto N, Naito Y, Anami K, Trang PT, et al: Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer. Gastric Cancer. 19:443–452. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kobayashi K, Nakahori Y, Miyake M, Matsumura K, KondoIida E, Nomura Y, Segawa M, Yoshioka M, Saito K, Osawa M, et al: An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature. 394:388–392. 1998. View Article : Google Scholar : PubMed/NCBI
20	Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S and Kodama K: Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res. 162:377–389. 2004. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH and Compton CC: TNM seventh edition: What's new, what's changed: Communication from the international union against cancer and the American Joint Committee on Cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
23	Cullings HM, Fujita S, Funamoto S, Grant EJ, Kerr GD and Preston DL: Dose estimation for atomic bomb survivor studies: Its evolution and present status. Radiat Res. 166:219–254. 2006. View Article : Google Scholar : PubMed/NCBI
24	Straume T, Rugel G, Marchetti AA, Rühm W, Korschinek G, McAninch JE, Carroll K, Egbert S, Faestermann T, Knie K, et al: Measuring fast neutrons in Hiroshima at distances relevant to atomic-bomb survivors. Nature. 424:539–542. 2003. View Article : Google Scholar : PubMed/NCBI
25	Saito F, Masaki T, Saito Y, Nakamura A, Takeda S, Shimizu T, Toda T and Matsumura K: Defective peripheral nerve myelination and neuromuscular junction formation in fukutin-deficient chimeric mice. J Neurochem. 101:1712–1722. 2007. View Article : Google Scholar : PubMed/NCBI